Thirty Respiratory Limited
6 clinical trials · Sponsor
◉ Watch Thirty Respiratory Limited
| Record | Firm | Date |
|---|---|---|
| Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis (NCT07073638) | Thirty Respiratory Limited | 2025-10-13 |
| Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa) (NCT06663176) | Thirty Respiratory Limited | 2024-10-16 |
| Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis (NCT06041919) | Thirty Respiratory Limited | 2023-09-27 |
| PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT) (NCT04842331) | Thirty Respiratory Limited | 2021-09-01 |
| COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2 (NCT04858451) | Thirty Respiratory Limited | 2021-03-01 |
Track Thirty Respiratory Limited automatically
Every clearance here is in the API, with alerts when new ones post.